ResourcesLearn from our biopharma experts, explore stimulating thought leadership and see some of our clients’ past successes.
The Prescient team has prepared a white paper discussing our view on the recent advances in the CAR-T landscape. Industry and academia appear to be making significant strides in simplifying manufacturing and administration processes, expanding clinical utility and enabling access for patients. By: Ben Doran, Stuart Crichton, Ben Druck and Vasiliki Patsioura Click below and complete the form to receive the white paper via email.Read More
By: Vania Galarraga, MPH, Engagement ManagerSkin diseases constitute one of the leading causes of health burden worldwide, measured as disability-adjusted life years (DALYs). Among skin diseases, psoriasis (PsO) carries the third-largest disability weight, which translates into health loss and poor quality of life (QoL)1. Globally, approximately 1-8% of the population suffers from PsO2, 3. Among PsO p[...]
By: Nick Turner, PhD, Senior Director Activating mutations in the EGFR gene are found in about 10-12% of all non-small cell lung cancer (NSCLC) cases and around 50% of cases in East-Asian patients. Cancer in patients with mutations is driven by constitutive activation of EGFR-signaling pathways due to acquired mutations in the catalytic domain of the receptor rendering them amenable to EGFR-tyrosine kinase[...]
By: Nick Turner, PhD, Senior DirectorLung cancer is the leading cause of cancer mortality worldwide, accounting for more than 1.6 million deaths annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all new cases. Current first-line treatment decisions for metastatic NSCLC mandate analysis of the genetic status of the cancer to determine the presence of driver mutations, such as activating mutat[...]
By: Nick Turner, PhD and Paula Palacios Fernandez, MScBreast cancer is the most common cancer in women with more than 2.1 million new cases diagnosed in 2018. And with more than 600,000 deaths in 2018, it is the second-leading cause of cancer deaths in women worldwide (WHO). Advances have been made across all stages and sub-types of the disease and provide hop[...]
By: Ben Doran, Stuart Crichton, Ben Druck and Vasiliki Patsioura.The Prescient team has prepared a white paper discussing our view on the recent advances in the CAR-T landscape. In this paper, we do not focus on the already well-documented challenges, but rather present ou[...]
By: Nick Turner, PhDA largely glossed-over finding from active-controlled trials of checkpoint inhibitors in solid tumors is the delayed crossover of Kaplan-Meier (K-M) survival curves, consistent with increased risk of disease progression and mortality early in checkpoint inhibitor immunotherapy (CPI). This raises the heretical proposition that CPI monotherapy may have a detrimental effect on progression an[...]
Our client was a global biopharmaceutical company with a market-leading brand more than 20 years’ old. It came under intense pricing pressure due to generic entries from companies known to play primarily on price.
Our global pharmaceutical client had a product whose patent was expiring within a year. The client wanted to understand the potential impact of generic competition on its brand in key revenue markets. Prescient was engaged to develop tactics to defend market share in these markets by:
Our client, a European specialty pharmaceutical company, was considering an expansion of indications within its target therapeutic group via licensing and acquiring products that were in clinical development, soon-to-be-launched or already marketed.
By: Vasiliki Patsioura, MScAccess to cancer therapies is a part of every country’s health policy agenda; it, however, is not guaranteed to the entire clinically eligible population. In the last five years, the market access landscape for cancer therapies has changed significantly with the addition of more treatment options, mainly immunotherapies. High-priced immune checkpoint inhibitors, a new class of[...]